Overview

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 3 randomized, placebo-controlled study designed to evaluate adalimumab in children 4 to 17 years old with polyarticular juvenile idiopathic arthritis (JIA) who are either methotrexate (MTX) treated or non-MTX treated.
Phase:
Phase 3
Details
Lead Sponsor:
Abbott
Treatments:
Adalimumab
Antibodies
Antibodies, Monoclonal